Pharma major Novartis falls 9% after three drug trial setbacks

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors. Novartis shares tanked on Tuesday after the pharmaceutical giant said its del-desiran drug for muscle-wasting disorder failed in a late-stage trial. The company's stock was last seen down 8.9%, as investors reacted to what was its third drug trial setback in a week [1].

Sources

1. cnbc.com · Pharma major Novartis falls 9% after three drug trial setbacks Sep 8, 2026
2. cnbc.com · Cholesterol drug setback casts doubt over multibillion-dollar race Sep 8, 2026

This is the neutral brief the press writes once, for everyone, before each reader’s paper adds its own so-what. It links out; it does not republish. 2 articles clustered.

Print your own paper